Literature DB >> 22996682

Multifaceted roles of PGE2 in inflammation and cancer.

Masako Nakanishi1, Daniel W Rosenberg.   

Abstract

Prostaglandin E(2) (PGE(2)) is a bioactive lipid that elicits a wide range of biological effects associated with inflammation and cancer. PGE(2) exerts diverse effects on cell proliferation, apoptosis, angiogenesis, inflammation, and immune surveillance. This review concentrates primarily on gastrointestinal cancers, where the actions of PGE(2) are most prominent, most likely due to the constant exposure to dietary and environmental insults and the intrinsic role of PGE(2) in tissue homeostasis. A discussion of recent efforts to elucidate the complex and interconnected pathways that link PGE(2) signaling with inflammation and cancer is provided, supported by the abundant literature showing a protective effect of NSAIDs and the therapeutic efficacy of targeting mPGES-1 or EP receptors for cancer prevention. However, suppressing PGE(2) formation as a means of providing chemoprotection against all cancers may not ultimately be tenable, undoubtedly the situation for patients with inflammatory bowel disease. Future studies to fully understand the complex role of PGE(2) in both inflammation and cancer will be required to develop novel strategies for cancer prevention that are both effective and safe.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22996682      PMCID: PMC3568185          DOI: 10.1007/s00281-012-0342-8

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   9.623


  147 in total

1.  PGE2 inhibits natural killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling.

Authors:  Ludovic Martinet; Christine Jean; Gilles Dietrich; Jean-Jacques Fournié; Rémy Poupot
Journal:  Biochem Pharmacol       Date:  2010-05-12       Impact factor: 5.858

2.  cPLA2 is protective against COX inhibitor-induced intestinal damage.

Authors:  David C Montrose; Krishna Kadaveru; Jillian N M Ilsley; Sierra H Root; Thiruchanduri V Rajan; Manish Ramesh; Frank C Nichols; Bruce T Liang; Dmitry Sonin; Arthur R Hand; Simona Zarini; Robert C Murphy; Glenn S Belinsky; Masako Nakanishi; Daniel W Rosenberg
Journal:  Toxicol Sci       Date:  2010-06-18       Impact factor: 4.849

3.  Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells.

Authors:  Magis Mandapathil; Miroslaw J Szczepanski; Marta Szajnik; Jin Ren; Edwin K Jackson; Jonas T Johnson; Elieser Gorelik; Stephan Lang; Theresa L Whiteside
Journal:  J Biol Chem       Date:  2010-06-17       Impact factor: 5.157

4.  Prostaglandin E2 induces contraction of liver myofibroblasts by activating EP3 and FP prostanoid receptors.

Authors:  S Ayabe; T Murata; T Maruyama; M Hori; H Ozaki
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

5.  Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.

Authors:  Paulo C Rodriguez; Marc S Ernstoff; Claudia Hernandez; Michael Atkins; Jovanny Zabaleta; Rosa Sierra; Augusto C Ochoa
Journal:  Cancer Res       Date:  2009-02-05       Impact factor: 12.701

6.  Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer.

Authors:  Michael G Backlund; Jason R Mann; Vijaykumar R Holla; Qiong Shi; Takikoku Daikoku; Sudhansu K Dey; Raymond N DuBois
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

Review 7.  Myeloid-derived suppressor cells as regulators of the immune system.

Authors:  Dmitry I Gabrilovich; Srinivas Nagaraj
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

8.  The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.

Authors:  Sung Yong Lee; Hye Kyoung Choi; Kyoung Ju Lee; Jin Yong Jung; Gyu Young Hur; Ki Hwan Jung; Je Hyeong Kim; Chol Shin; Jae Jeong Shim; Kwang Ho In; Kyung Ho Kang; Se Hwa Yoo
Journal:  J Immunother       Date:  2009-01       Impact factor: 4.456

Review 9.  Regulatory lymphocytes and intestinal inflammation.

Authors:  Ana Izcue; Janine L Coombes; Fiona Powrie
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

10.  Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling.

Authors:  Katia Boniface; Kristian S Bak-Jensen; Ying Li; Wendy M Blumenschein; Mandy J McGeachy; Terrill K McClanahan; Brent S McKenzie; Robert A Kastelein; Daniel J Cua; René de Waal Malefyt
Journal:  J Exp Med       Date:  2009-03-09       Impact factor: 14.307

View more
  189 in total

1.  Prostaglandin E2 Reverses the Effects of DNA Methyltransferase Inhibitor and TGFB1 on the Conversion of Naive T Cells to iTregs.

Authors:  Mehmet Sahin; Emel Sahin
Journal:  Transfus Med Hemother       Date:  2019-09-19       Impact factor: 3.747

Review 2.  Control of local immunity by airway epithelial cells.

Authors:  M Weitnauer; V Mijošek; A H Dalpke
Journal:  Mucosal Immunol       Date:  2015-12-02       Impact factor: 7.313

3.  Prostaglandin E2 activates the mTORC1 pathway through an EP4/cAMP/PKA- and EP1/Ca2+-mediated mechanism in the human pancreatic carcinoma cell line PANC-1.

Authors:  Hui-Hua Chang; Steven H Young; James Sinnett-Smith; Caroline Ei Ne Chou; Aune Moro; Kathleen M Hertzer; Oscar Joe Hines; Enrique Rozengurt; Guido Eibl
Journal:  Am J Physiol Cell Physiol       Date:  2015-08-26       Impact factor: 4.249

Review 4.  The role of dendritic cells in cancer.

Authors:  Morten Hansen; Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2016-09-16       Impact factor: 9.623

5.  Prostaglandins D2 and E2 have opposite effects on alveolar macrophages infected with Histoplasma capsulatum.

Authors:  Priscilla A T Pereira; Patrícia A Assis; Morgana K B Prado; Simone G Ramos; David M Aronoff; Francisco W G de Paula-Silva; Carlos A Sorgi; Lúcia H Faccioli
Journal:  J Lipid Res       Date:  2017-12-07       Impact factor: 5.922

6.  Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II.

Authors:  Howard Y Li; Maria McSharry; Deandra Walker; Amber Johnson; Jeff Kwak; Bonnie Bullock; Alexander Neuwelt; Joanna M Poczobutt; Trisha R Sippel; Robert L Keith; Mary C M Weiser-Evans; Eric Clambey; Raphael A Nemenoff
Journal:  Oncoimmunology       Date:  2018-02-13       Impact factor: 8.110

7.  Prostaglandin E2 Inhibits NLRP3 Inflammasome Activation through EP4 Receptor and Intracellular Cyclic AMP in Human Macrophages.

Authors:  Milena Sokolowska; Li-Yuan Chen; Yueqin Liu; Asuncion Martinez-Anton; Hai-Yan Qi; Carolea Logun; Sara Alsaaty; Yong Hwan Park; Daniel L Kastner; Jae Jin Chae; James H Shelhamer
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

Review 8.  Non-coding RNAs: the new central dogma of cancer biology.

Authors:  Phei Er Saw; Xiaoding Xu; Jianing Chen; Er-Wei Song
Journal:  Sci China Life Sci       Date:  2020-09-11       Impact factor: 6.038

Review 9.  Thrombospondin-1 interactions regulate eicosanoid metabolism and signaling in cancer-related inflammation.

Authors:  Manuel U Ramirez; Elizabeth R Stirling; Nancy J Emenaker; David D Roberts; David R Soto-Pantoja
Journal:  Cancer Metastasis Rev       Date:  2018-09       Impact factor: 9.264

10.  The syndecan-4/protein kinase Cα pathway mediates prostaglandin E2-induced extracellular regulated kinase (ERK) activation in endothelial cells and angiogenesis in vivo.

Authors:  Federico Corti; Federica Finetti; Marina Ziche; Michael Simons
Journal:  J Biol Chem       Date:  2013-03-22       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.